Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract
There is significant number of evidences suggesting the anti-inflammatory properties of gum resin extracts of Boswellia serrata containing 3-O-acetyl-11-keto-β-boswellic acid (AKBA) and their promising potential as therapeutic interventions against inflammatory diseases such as osteoarthritis (OA). Unfortunately, the poor bioavailability of AKBA following oral administration might limit the anti-inflammatory efficacy of standardized Boswellia extract(s). To address this issue, we describe a novel composition called Aflapin, which contains B. serrata extract enriched in AKBA and non-volatile oil portion of B. serrata gum resin. Our observations show that the availability of AKBA in systemic circulation of experimental animals is increased by 51.78% in Aflapin-supplemented animals, in comparison with that of 30% AKBA standardized extract or BE-30 (5-Loxin®). Consistently, Aflapin confers better anti-inflammatory efficacy in Freund’s Complete Adjuvant (FCA)-induced inflammation model of Sprague–Dawley rats. Interestingly, in comparison with BE-30, Aflapin® also provides significantly better protection from IL-1β-induced death of human primary chondrocytes and improves glycosaminoglycans production in human chondrocytes. In Tumor necrosis factor alpha (TNFα)-induced human synovial cells, the inhibitory potential of Aflapin (IC50 44.736 ng/ml) on matrix metalloproteinase-3 (MMP-3) production is 14.83% better than that of BE-30 (IC50 52.528 ng/ml). In summary, our observations collectively suggest that both the Boswellia products, BE-30 (5-Loxin®) and Aflapin, exhibit powerful anti-inflammatory efficacy and anti-arthritic potential. In particular, in comparison with BE-30, Aflapin provides more potential benefits in recovering articular cartilage damage or protection from proteolytic degradation due to inflammatory insult in arthritis such as osteoarthritis or rheumatoid arthritis.
Keywords3-O-acetyl-11-keto-β-boswellic acid Aflapin Boswellia serrata Chondrocytes Matrix metalloproteinase-3 Osteoarthritis
We sincerely thank Sri G Ganga Raju, Chairman; Mr. G Rama Raju, Director; and Mr. B. Kiran, CEO of Laila Group of Industries, India for their generous support and encouragements. We also thank Mr. K Gopal Rao for his help in analyzing serum samples for the bio-availability study. This study was supported by Laila Nutraceuticals, Vijayawada, India.
The authors declare there are no competing interests.
- 9.Gokaraju G, Gokaraju R, Gottumukkala VS, Golakoti T, Pratha S. Process for producing a fraction enriched up to 100% 3-O-acetyl-11-keto-beta boswellic acid from an extract containing a mixture of boswellic acid. Indian Patent # 205269Google Scholar
- 10.Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss HG, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Bagchi D, Sen CK (2005) Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in micro vascular endothelial cells. DNA Cell Biol 24:244–255CrossRefPubMedGoogle Scholar
- 11.Roy S, Khanna S, Krishnaraju AV, Subbaraju GV, Yasmin T, Bagchi D, Sen CK (2006) Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. Antiox Redox Signal 3&4:653–660Google Scholar
- 12.Sengupta K, Golakoti T, Marasetti A, Tummala T, Ravada S, Krishnaraju A, Siba P, Raychaudhuri SP (2009) 30% 3-O-acetyl-11-keto-β-boswellic acid inhibits TNFα production and blocks MAPK/NFκB activation in lipopolysaccharide induced THP-1 human monocytes. J Food Lipids 16:325–344CrossRefGoogle Scholar
- 34.van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM (1994) A tetrazolium based colorimetric MTT assay to quantitate human monocytes mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174:311–320CrossRefPubMedGoogle Scholar
- 38.Poole AR (1997) Arthritis and allied conditions. In: Koopman WJ (ed) A textbook of rheumatology. Williams and Wilkins, Baltimore, pp 255–308Google Scholar